Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Oct 6 2022

Full Issue

HHS Spends $290 Million On Extra Radiation Sickness Medication

It could be a "troubling sign of the times," FiercePharma says, noting the money is buying an "undisclosed" amount of the Amgen drug Nplate — approved to treat blood cell injuries from acute radiation sickness. The Department of Health and Human Services downplayed the purchase.

FiercePharma: Sign Of The Times? US Stocks Up On Amgen's Radiation Sickness Drug Nplate 

In what could be a troubling sign of the times, the United States is stocking up on radiation sickness drugs. Wednesday, the U.S. Department of Health and Human Services (HHS) said it’s throwing down $290 million to lock up an undisclosed amount of Amgen’s blood disorder med Nplate, which is approved to treat blood cell injuries linked to acute radiation syndrome (ARS) in kids and adults. (Kansteiner, 10/5)

In its press release, HHS downplayed the purchase as "part of long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies" —

HHS purchases drug for use in radiological and nuclear emergencies

The Register: US Intelligence Researches Improved Radiation Detection 

The research arm of US intelligence has begun investigating methods for spotting low doses of ionizing radiation to better protect American service personnel and provide evidence of nuclear technology use. The Intelligence Advanced Research Projects Activity (IARPA) announced the start of Targeted Evaluation of Ionizing Radiation Exposure (TEI-REX) on [Sept. 30], which will look for non-invasive methods of determining radiation exposure in low doses through samples including hair, skin, sweat, and saliva. (Vigliarolo, 9/30)

The New York Times: Russia’s Small Nuclear Arms Are A Risk For Putin And Ukraine 

How much destruction — and lingering radiation — would result depends on factors including the size of the weapon and the winds. But even a small nuclear explosion could cause thousands of deaths and render a base or a downtown area uninhabitable for years. ... The radiation dangers from small nuclear arms would likely be less than those involving large reactors, like those at Chernobyl. Its radioactive fallout poisoned the flatlands for miles around and turned villages into ghost towns. Eventually the radiation caused thousands of cases of cancer, though exactly how many is a matter of debate. (Sanger and Broad, 10/3)

The Washington Post: Here Are The Nuclear Weapons Russia Has In Its Military Arsenal 

It is very unlikely that Russia would use its most powerful nuclear weapons to settle scores with Kyiv; Moscow is far more likely, experts agree, to use a smaller nuclear weapon in the hopes of achieving a specific battlefield objective. But, those same experts caution, once a nuclear weapon is unleashed, controlling what happens next is difficult. (Demirjian, 10/5)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF